Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Chronic heart failure (CHF) management involves various medications.
• The role of digoxin in CHF patients receiving beta-blockers like carvedilol requires clarification.
• Previous studies have yielded mixed results on digoxin's efficacy and safety in CHF.

Purpose of the Study:

• To investigate the impact of digoxin on clinical outcomes in patients with chronic heart failure who were randomized to receive either carvedilol or placebo.
• To analyze the safety and efficacy of digoxin in a large, diverse patient population with advanced heart failure.

Main Methods:

• Retrospective analysis of 1,509 patients from 4 multicenter US studies and 1 Australia-New Zealand study.
• Stepwise logistic regression was employed to analyze the data.
• Patients were stratified based on digoxin use (digoxin vs. no-digoxin) within carvedilol or placebo groups.

Main Results:

• Patients receiving digoxin presented with more advanced stages of chronic heart failure.
• There was no significant difference in the incidence of all-cause hospitalization between the digoxin and no-digoxin groups.
• The combined endpoint of all-cause death and all-cause hospitalization showed no difference between the digoxin and no-digoxin groups.

Conclusions:

• Digoxin use in patients with advanced chronic heart failure treated with carvedilol was not associated with an increased risk of hospitalization or death.
• These findings suggest that digoxin can be safely used in this patient population.
• Further research may be warranted to explore potential benefits or specific subgroups where digoxin might be more advantageous.